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Abstract The five-year survival rate for primary bone
cancers is * 70% while almost all cases of secondary
metastatic bone cancer are terminal. Hypoxia, the defi-
ciency of oxygen which occurs as the rate of tumour
growth exceeds the supply of vascularisation, is a key
promoter of tumour progression. Hypoxia-driven effects in
the primary tumour are wide ranging including changes in
gene expression, dysregulation of signalling pathways,
resistance to chemotherapy, neovascularisation, increased
tumour cell proliferation and migration. Paget’s seed and
soil theory states that for a metastasising tumour cell ‘the
seed’ it requires the correct microenvironment ‘soil’ to
colonise. Why and how metastasising tumour cells colonise
the bone is a complex and intriguing problem. However,
once present tumour cells are able to disrupt bone home-
ostasis through increasing osteoclast activity and down-
regulating osteoblast function. Osteoclast resorption
releases growth factors from the bone matrix that subse-
quently contribute to the proliferation of invasive tumour
cells creating the vicious cycle of bone loss and metastatic
cancer progression. Recently, we have shown that hypoxia
increases expression and release of lysyl oxidase (LOX)
from primary mammary tumours, which in turn disrupts
bone homeostasis to favour osteolytic degradation to create
pre-metastatic niches in the bone microenvironment. We
also demonstrated how treatment with bisphosphonates
could block this cancer-induced bone remodelling and
reduce secondary bone metastases. This review describes
the roles of hypoxia in primary tumour progression to
metastasis, with a focus on key signalling pathways and
treatment options to reduce patient morbidity and increase
survival.
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An Introduction to Hypoxia
Hypoxia is the deficiency of oxygen that commonly occurs
within tumours. There are two broad classes of hypoxia,
transient hypoxia which is associated with inadequate
blood flow, while chronic hypoxia is the consequence of
the increased oxygen diffusion distance due the rate of
tumour growth exceeding the rate of neovascularisation
[1]. Both types of hypoxia are clinically correlated with
poor outcome for patients. The presence of hypoxia and the
lack of vascularisation represent a double-edged sword of
stimuli for cancer progression and obstacles against cancer
treatment. Hypoxia triggers changes in gene expression
that contribute to tumour progression via several mecha-
nisms including neovascularisation and increases in cell
proliferation, motility, and migration leading to metastasis
[2–4]. Treatment of hypoxic cancers is impeded in several
ways including (i) the lack of functional vasculature
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reduces access of chemotherapeutic drugs to cancers via
the circulatory system; (ii) changes in acidity as a result of
hypoxia alter the stability and activity of chemotherapeutic
agents; (iii) some chemotherapeutic drugs require oxygen
to generate free radicals that contribute to their cytotoxic-
ity; (iv) hypoxia typically reduces the rate of proliferation
of cancer cells, the very mechanism which chemotherapy
targets; and (v) through hypoxia-induced chemoresistance
within cancer cells mediated through adaptation by post-
translational and transcriptional changes [5].
Epidemiology and Roles of Hypoxia in Primary
Bone Cancers
Hypoxia decreases survival rates in all primary bone can-
cers. The most common is osteosarcoma which arises from
primitive bone forming mesenchymal cells and accounts
for 56% of all cases of primary bone cancer [6]. For
osteosarcoma 5-year survival rates are age related
with * 60% survival for patients under 19 years of age [6]
and just 30% for those aged 50 and over [7]. Immunohis-
tochemical labelling for the hypoxia marker HIF-1a in
clinically derived osteosarcoma tumour samples correlates
with pathologic stage, and tumours from patients with
medium to strong HIF-1a expression had decreases in both
overall survival and disease-free survival [8].
Ewing sarcoma is the second most common paediatric
primary bone cancer after osteosarcoma, accounting for
34% of malignant bone tumours with a 58% five-year
survival rate for children and adolescents [6]. One study
has suggested that ES patients aged 26 and above are in the
highest risk group, since response to chemotherapy was
only observed in 50% of patients with localised disease,
and just 9% of patients with metastatic disease. The five-
year survival rate in this group is only 37% [9]. In Ewing
sarcoma, hypoxia-induced expression of HIF-1a has been
shown in primary ES tumours [10] and co-localises with
the programmed cell death-associated protein caspase 3
[11].
Chondrosarcoma is a neoplastic cartilage tumour that is
rare in children but more common in adults making it the
third most common paediatric primary bone cancer but the
second most common in adults [6]. Five-year survival rates
vary tremendously with progression of chondrosarcoma
from 93% in juxtacortical chondrosarcoma to 0% in ded-
ifferentiated chondrosarcoma where most patients die
within a year of diagnosis [12]. In clinical samples of high-
grade chondrosarcoma, elevated levels of HIF-1a inducible
matrix metalloprotease 2 and galectin 1 have been detec-
ted, consistent with increased hypoxia signalling [13, 14].
In primary cancers, hypoxia is often the key driver of
progression to the point where metastasis to other organs
occur. This is particularly important in multiple myeloma,
a cancer of the plasma cells in bone marrow which spreads
to the calcified portion of the bone, and primary cancers of
breast and prostate which are also highly bone tropic
leading to secondary bone cancers.
Pathways and Mechanisms of Hypoxia-Induced
Cancer Progression in Primary Bone Cancers
HIF-1a–VEGF–CXCR4 Pathway
The most important mediators of the cellular response to
hypoxia are the transcription factor hypoxia inducible
factors 1 and 2 (HIF-1 and HIF-2) [15]. The best studied is
HIF-1, a heterodimer of the HIF1a and HIF1b two sub-
units. The functionality of HIF-1 as it drives the response
of the tumour to hypoxia is determined by the availability
of HIF1a, which is up-regulated under hypoxia. HIF1a is
an upstream regulator of vascular endothelial growth factor
(VEGF), a signal protein that promotes angiogenesis by
acting upon the VEGF receptors VEGFR1 and VEGFR2
(the latter also known as kinase insert domain receptor)
[16]. HIF1-a and VEGF drive expression of C-X-C che-
mokine receptor type 4 (CXCR4), a chemokine receptor for
stromal cell-derive factor-1 (SDF-1) a (also known as
CXCL12). There is evidence that HIF1a directly induces
VEGF and CXCR4 transcription by binding to hypoxia
response element regions [17], while VEGF has also been
implicated in CXCR4 upregulation of angiogenic vessels in
glioblastoma [18]. As such, it has been shown that the HIF-
1a–VEGF–CXCR4 axis is a key driver in primary bone
cancers and many of its effects can be prevented with the
CXCR4 inhibitor AMD3100 [19, 20].
HIF-1a is responsible for multiple effects that have been
associated with enhanced cancer progression and poorer
patient outcome. These include enhanced tumour cell
proliferation [21, 22], migration [21, 23, 24], and metas-
tasis [10, 23, 25]. In primary osteosarcoma, HIF-1a
expression in tumour biopsies is seen to be significantly
correlated with metastasis, and in vitro data reveal that
VEGF expression driven by HIF-1a is associated with cell
migration [26]. In Ewing sarcoma cells, siRNA interfer-
ence of HIF1-a in vitro reduces the hypoxic induction of
VEGF [11]. Clinically, serum VEGF is elevated in patients
with ES, which correlates strongly with expression of
HIF1-a in the primary tumour [27]. In ES, tumour cells that
line blood lakes were shown to express HIF-1a which co-
localised with the hypoxia marker pimonidazole in con-
junction with vasculogenic mimicry [28]. In ES cells,
siRNA interference of HIF1-a in vitro also reduces hypoxic
induction of VEGF [11]. Clinically, serum VEGF is ele-
vated in patients with ES, which correlates strongly with
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expression of HIF1-a in the primary tumour [27]. Although
normal healthy cartilage is typically a hypoxic avascular
tissue supplied only via diffusion, chondrosarcoma is vas-
cularised. This is likely the result of the elevated HIF-1a,
observed in chondrosarcoma biopsies, and is required for
hypoxia-induced VEGF expression in chondrosarcoma cell
lines [29]. Hypoxia selectively augments CXCR4 expres-
sion through HIF-1 activation in several cell types
including cancer cells [30]. Hypoxia increases CXCR4
expression in both ES and chondrosarcoma cell lines grown
in vitro or as tumours in vivo in nude mice [31, 32]. This
was associated with increased VEGF secretion in vitro
detectable by ELISA and the functional endothelial cell
tubule formation assay, a proxy for vascularisation [32].
The subsequent ES cell migration (which can be inhibited
by AMD3100) is driven towards the CXCR4 ligand stro-
mal cell-derived factor (SDF1)-a which is commonly
found in sites of metastasis in vivo [31].
In osteosarcoma, cell invasion across transwells in vitro
is increased under hypoxic conditions reliant upon HIF-1a
promoting VEGF-A expression [26]. This could be
decreased by inhibition of HIF-1a, or treatment with the
anti-CXCR4 drug AMD3100 [26, 33]. Of note, hypoxia-
treated osteosarcoma cells injected into the tail vein of
mice led to increased lung metastases compared to nor-
moxic controls, an effect that was ablated if cells were also
pre-treated with AMD3100 [33]. Finally, in a mouse model
of chondrosarcoma, siRNA inhibition of CXCR4 decreased
overall tumour volume and incidence of metastases to the
lungs [32]. Overall, expression of CXCR4 is a poor prog-
nostic indicator that is associated with an increase in many
of the processes that are associated with cancer progression
including cell migration and metastasis.
HIF-1a is also up-regulated in breast and prostate can-
cers [34]. In breast cancers with stromal fibroblasts that
secrete SDF-1 and CXCL-12, the tumours exhibit
increased growth, angiogenesis and invasion [35]. Some of
the response of breast cancer to CXCR4 may be deter-
mined by the presence of estrogen receptors, as the CXCl-
12 signalling axis is important for the estrogen-mediated
growth of breast cancer cells [36]. The presence of CXCR4
has also been shown to correlate with metastatic disease in
prostate cancer, where xenograft tumours that over
expressed CXCR4 grafted into immunodeficient NOD/
SCID mice exhibited increased growth, vessel density and
metastasis [37]. As in primary bone tumours, expression of
CXCR4 causes cancer progression, and, in the case of
breast or prostate cancer, may increase the risk of metas-
tasis to bone.
The Neuropeptide Y-Dipeptidyl Peptidase-IV Axis
There are certain signalling pathways that are specific to
individual types of cancer. In ES, the main underlying
cause is chromosomal translocation resulting in the pro-
duction of fusion oncoprotein. In * 90% of all cases, this
involves the fusion of the amino-terminal of the Ewing
sarcoma breakpoint region 1 gene (EWSR1) with the
DNA-binding domain of the ETS gene family member
FLI1 to generate the EWS-FLI1 fusion protein [38, 39].
Neuropeptide Y (NPY) is a transcriptional target of the
fusion oncoprotein EWS-FLI1. Elevated release of NPY by
Ewing sarcoma tumours is associated with site-specific
metastasis including thoracic extra-osseous, bone and
brain. Use of short hairpin RNA (shRNA) to reduce NPY
expression in an Ewing sarcoma cell line then injected into
mice exhibited, reduced bone destruction as quantified by
lCT [38]. While shRNA may not be readily translatable to
the clinic, selective radiolabelled peptides have recently
been investigated as potential NPY therapies [40]. Such
radiolabelled peptides have been used clinically for nearly
three decades for a range of treatments, the first being an
analogue for the growth hormone-inhibiting molecule
somatostatin. In cancer, radiolabelled peptides are also
used to bind specific membrane-associated receptors
enabling targeted delivery of molecules for the detection
and treatment [41]. Examples of this include, a radiola-
belled Neuropeptide Y analogue which can be internalised
by neuroblastoma cells [42], a radiolabelled luteinizing
hormone releasing hormone which selectively binds to
ovarian cancer cells in vivo to enhance cell apoptosis [43],
and the somatostatin analogue octreotide (Sandostatin) for
treatment of neuroendocrine tumours [44]. However, to our
knowledge, no radiolabelled peptides have been used to
target Ewing sarcoma.
Under normoxic conditions, NPY acts upon the Y1R
and Y5R receptors to stimulate cell death in Ewing sar-
coma; however, hypoxia alters the expression of NPY
receptors by inducing Y2R expression instead. Hypoxia
also increases the expression of the enzyme dipeptidyl
peptidase IV (DPP-IV) which truncates NPY. The resulting
NPY3-36 does not bind Y1R to induce cell death but acts
as selective agonist on Y2R. Hypoxia also increases
expression of Y2R on endothelial cells which are sensitive
to NPY3-36 to drive angiogenesis. Furthermore, DPP-IV
drives proliferation and migration of ES cells [45]. A
clinical study by the same group recently found that NPY
was systemically increased in Ewing sarcoma patients and
was associated with metastasis [46]. Although direct clin-
ical targeting of DPP-IV has not been investigated in
Ewing sarcoma, it has been widely investigated in other
diseases where DPP-IV is known to be a contributing
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factor. To date, there are several inhibitors of DPP-IV that
are being given to diabetes patients [47], yet to the best of
our knowledge there are no reports available of DPP-IV
inhibitors being used to treat Ewing sarcoma.
Targeting Hypoxia in Primary Tumours
One way to turn the tables on hypoxia-driven chemore-
sistance is to develop therapies that rely on, or directly
target hypoxia-driven effects or the hypoxic microenvi-
ronment. One such approach utilises bioreductive or
hypoxia-activated pro-drugs (HAPs), where the central
premise is that inactive pro-drugs are delivered to the
hypoxic regions of the tumour whereupon they are enzy-
matically activated, or spontaneously reduced to release
their cytotoxic payloads that target cancer cells. This
approach works best where hypoxia within the tumour of
the patient is seen to be responsible for the failure of
standard-of-care treatment [48].
There are several HAPs that have either recently or are
currently undergoing clinical trials including AQ4N, PR-
104, and TH-302. AQ4N becomes AQ4 after activation in
hypoxic conditions whereupon it non-covalently binds to
DNA to facilitate anti-tumour activity and selectively
inhibits the activity of the DNA separation enzyme topoi-
somerase II [49]. Mice injected with LNCaP prostate
tumour cells and treated with AQ4N in conjunction with
the anti-androgenic drug bicalutamide exhibited delayed
tumour growth which was significantly greater than bica-
lutamide alone [50]. AQ4N has been delivered to human
breast tumours as part of a phase I clinical trial [51] and
shown promise. However to date, there are no studies
available where AQ4N has been used in primary bone
cancers either in vitro or in vivo.
PR-104 is a phosphate ester that is hydrolysed and then
reduced under hypoxic conditions to release amine and
hydroxyl-amine nitrogen mustards that selectively cross-
link DNA in hypoxic cells [52]. PR-104 has been given to
patients with acute myeloid and acute lymphoblastic leu-
kaemia in phase I/II trials whereupon measurable anti-
leukaemic responses were observed at doses of 3 g/m2 and
above [52].
TH-302 (evofosfamide) is a nitroazole-containing pro-
drug that selectively releases bromo-isophosphoramide
which cross-links DNA [53, 54]. In the clinic, TH-302 has
been tested in phase I trials against relapsed/refractory leu-
kaemia where it had little effect [55]. Although phase II
trials of TH-302 together with the chemotherapy drug dox-
orubicin in patients with soft tissue sarcoma have suggested
a favourable response, in line with other first line
chemotherapies [56]. However, a recent phase III trial found
that TH-302 with doxorubicin did not increase survival
compared to doxorubicin alone [57]. Other phase III clinical
trials of TH-302 in pancreatic cancer found no significant
increase in 1-year survival rate with TH-302 and although
there was a small yet significant increase in progression-free
survival this study did not reach primary overall survival
endpoints [58, 59]. These data suggest that while TH-302
may have some limited effect on survival, it varies
depending upon the specific form of cancer. While clinical
trial data are not yet available to assess the potential of pro-
drugs such as TH-302 on primary bone cancers, the effects
of TH-302 have been studied by in vitro and in vivo meth-
ods. Bone destruction around the tumour site created by
osteosarcoma cells after injection into the tibial marrow
cavity of nude mice is reduced by TH-302 administration,
which also reduces the incidence of metastases to lung [60]
which at least suggests a mechanism by which TH-302
might work if applied to human disease. The potential role
for TH-302 in combatting chondrosarcoma at a very early
stage has been highlighted in one study which showed that
hypoxic regions of in vitro chondrosarcoma cell spheroids
exhibit a cytotoxic response to TH-302 [61]. Furthermore,
TH-302 triggers cell cycle arrest and apoptosis in multiple
myeloma cells under hypoxic conditions, while in vivo
treatment of the 5T33MM mouse model of multiple mye-
loma with TH-302 triggered apoptosis of multiple myeloma
cells within the bone microenvironment [62]. Adding to this
body of evidence, mice transplanted with osteolytic MDA-
MB-231-TXSA, the treatment with TH-302 was found to be
selectively cytotoxic under hypoxic conditions and able to
suppress tumour growth [63]. In another in vivo study, TH-
302 worked with doxorubicin treatment to enhance anti-
cancer effects in hypoxic regions, but it was found to
increase toxicity mirroring that seen in clinical trials for this
combination in soft tissue sarcoma [64]. TH-302 has also
been tested in combination with the chemotherapeutic drug
docetaxel against prostate cancer in a murine xenograft
model with the PC-3 cell line, whereupon it had no addi-
tional effect to docetaxel alone. However, a separate study
reported that TH-302 in combination with docetaxel had an
enhanced growth delay effect on tumours in athymic nude
mice with PC-3 cells [65]. The fact these two separate
studies both investigating the effect of TH-302 upon mice
injected with PC-3 prostate cancer cells can show such
different results strongly suggests that the working
requirements for TH-302may be specific not only to the type
of cancer under investigation, but also to the specific com-
bination of other chemotherapeutic agents used, the strain of
mouse model and other holistic considerations. These
studies suggest that in conjunction with the correct combi-
nation of chemotherapeutic drugs, TH-302 might be useful,
not only for targeting hypoxic primary bone tumours, but
also cancers that have a tendency to spread to bone after
metastasis.
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Another ‘hypoxia targeting’ approach entails the direct
targeting of HIF at the mRNA and protein levels. There are
a number of micro RNAs that act as inhibitors of HIF-1a in
healthy tissues but are downregulated in cancers allowing
for an increase in HIF-1a expression such as miR-33b
which is downregulated in osteosarcoma [21] and onco-
suppressive in breast cancer tissues [66]. Overexpression of
miR-33b in osteosarcoma cell lines reduces HIF-1a toge-
ther with cellular proliferation and migration [21].
Although it is intriguing to note that targeting a specific
microRNA under in vitro conditions can be used to mod-
ulate HIF-1a expression in cell lines, this is still a long way
from any clinical application. RNA is an inherently
unstable molecule so delivery of RNA in such a way that a
patient may benefit from it is a huge challenge. Lung tissue
has been a particular target for RNA delivery as the RNA
may be deliverable via inhaler [67] but delivery to tumours
that are not located within the lung poses a greater chal-
lenge. There is at least one ongoing phase I clinical trial
targeting multiple solid tumours (including multiple mye-
loma) with a mimic for the apoptosis regulator miR-34
delivered via lipid nanoparticles [68]. Although potentially
very exciting, at the time of writing the results of this trial
(NCT01829971) are yet to be reported. The function of
HIF-1 can also be interrupted at the protein level. Acri-
flavine, a drug which is more widely used as an antiseptic,
binds directly to HIF-1a protein to prevent dimerization
with HIF-1b thereby preventing the formation of functional
HIF-1 heterodimer. This approach has been used to drive
an arrest in the growth of PC-3 prostate cancer xenografts
in severe combined immune deficiency (SCID) mice [69].
More recently, Acriflavine has been demonstrated to
enhance the anti-tumour activity of the tyrosine kinase
inhibitor Sunitinib in the syngeneic 4T1 breast cancer cell
and BALB/c mouse model [70]. Overall, these studies
demonstrate that multipronged approaches for targeting the
overexpression of HIF-1 in response to hypoxia may yield
promising results.
Secondary Bone Cancers
All secondary metastatic bone cancers begin as primary
cancers elsewhere in the body. The primary cancers, typi-
cally triggered by hypoxia, undergo progression to metas-
tasis at which point the cells of bone-tropic cancers can
invade the skeletal system. It has been well over a century
since Stephen Paget’s visionary seed and soil hypothesis of
1889, when he wrote ‘‘When a plant goes to seed, its seeds
are carried in all directions; but they can only live and grow
if they fall on congenial soil’’ [71]. While this incisive
analogy has stood the test of time in many ways, it is an
over simplification to suggest that metastatic cancers
simply ‘‘fall’’ into the bone, instead it may be more accu-
rate to state that bone-tropic cancers actively home into
bone [72].
Once metastatic cancer cells colonise the bone
microenvironment, they initiate a dysregulation of bone
homeostasis typically referred to as the ‘vicious cycle’
[73]. Under normal conditions, the bone forming activities
of osteoblasts and resorbing activities of osteoclasts are
coupled. Localised autocrine and paracrine intercellular
signalling together with systemic factors regulate the co-
ordinated activities of osteoblasts and osteoclasts to
maintain healthy bone metabolism [74]. This tightly reg-
ulated system becomes disrupted by the arrival of meta-
static cancer cells to the bone microenvironment, which
secrete osteoclast stimulating factors that drive increased
osteoclastic activity and osteolysis. As a result of increased
bone turnover, there is an increase in the release of
sequestered bone-derived growth factors that subsequently
promote growth of the metastatic cancer cells. The result of
the vicious cycle is net bone loss in osteolytic lesions that
is associated with hypercalcemia, increased risk of bone
fracture and intense neuropathic pain [75]. Some of these
effects can be controlled at least temporarily by treatment
with anti-resorptive bisphosphonate drugs that bind cal-
cium in the bone and trigger apoptosis when resorbed by
osteoclasts [76]. Another approach is to target receptor
activator of nuclear factor-jb (RANK) ligand (RANKL),
the main protein required for osteoclast differentiation,
which can be blocked with the monoclonal antibody
denosumab [77].
In the 128 years since Paget’s hypothesis much has been
learnt about how cancers spread to bone, yet despite this
length of time and research, secondary metastatic bone
cancer remains a terminal condition. In the following
sections, this review will discuss what is known about
some of the most important secondary metastatic cancers
of the bone, and how revelatory paradigm shifts in our
understanding of secondary bone cancers could help to
improve future outcomes.
Multiple Myeloma
Multiple myeloma (MM) is a cancer of the plasma cells
located within the bone marrow which metastasises to the
cortical and trabecular bone. The first study to investigate
the interaction between bone marrow hypoxia and MM
utilised the 5T2MM myeloma mouse model to demonstrate
that although healthy and myelomatous bone marrow is
hypoxic, the environment is more hypoxic in myelomatous
bone marrow. These differences in hypoxia were mirrored
by HIF1-a expression levels in the myelomatous bone
marrow. Expression of HIF1-a was highest across all
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populations of 5T2MM cells in the pre-angiogenic stage,
suggesting that microvessel density is increased in
myelomatous bone marrow to decrease hypoxia concomi-
tantly with increased HIF-1a expression. Under in vitro
hypoxic conditions, CD45- MM cells underwent apoptosis
while tumour infiltrating CD45? MM did not, suggesting
that hypoxia is most important in the early stages of MM
progression [78]. The role of HIF-1a in MM was expanded
upon in a subsequent study that identified high constitutive
expression of HIF-1a in MM cells. Under healthy condi-
tions HIF-1a inhibits c-Myc activity, but in MM deregu-
lated c-Myc becomes oncogenic and facilitates HIF-1a
induced VEGF production and secretion to increase
angiogenesis [79]. Indeed, in clinical biopsies, HIF-1a and
VEGF receptor expression (in the phosphorylated active
form of VEGFR2/KDR) were up-regulated in 40% of
samples and were associated with increased angiogenesis
[80]. Intuitively, suppression of HIF-1a in MM cells
downregulates pro-angiogenic genes including VEGF and
subsequently reduces tumour burden in both subcutaneous
and intratibial mouse models of MM. This was shown to be
by reducing VEGF expression and vessel number within
tumours which had the additional beneficial effect of
reducing bone destruction [81]. In addition to increased
angiogenesis, hypoxia can promote epithelial to mes-
enchymal transition of MM cells. This results in a
decreased expression of E-cadherin, which is thought to
make MM cells less adhesive, and allow them to invade
and enter into the blood stream and travel to new sites to
form secondary metastasis in organs such as the bone. MM
cells are chemotactically attracted to sites of hypoxia-in-
duced CXCR4 expression, an effect that can be blocked by
AMD3100 [82]. As with many other cancers, there is a
switch between expression of E-cadherin and N-cadherin
during the epithelial–mesenchymal transition (EMT) of
MM. Expression of E-cadherin is decreased in response to
hypoxia [82]. N-cadherin expression has been associated
with increased integrin-a8 expression where increased
N-cadherin has been observed in LP1 and RPMI-8226 MM
cells and coincides with elevated expression of integrin-a8.
Thus, it is thought to drive expression of genes associated
with stemness including HIF-1a [83]. Clinically, N-cad-
herin expression is found in malignant plasma cells from a
subset of MM patients, and injection of labelled MM cells
into mice has revealed that increased expression of
N-cadherin helps to retain MM cells in the bone marrow.
Finally, in vitro co-cultures of N-cadherin expressing MM
cells with pre-osteoblastic cells acts to inhibit osteoblas-
togenesis [84]. Thus, hypoxia can be seen to increase
angiogenesis via multiple pathways, to drive EMT of MM,
and chemotaxis of metastatic MM cells to the mineralised
bone. Intriguingly, an in vitro study on hypoxia-resistant
MM cells found that these cells secreted an increased
number of exosomes compared to parent cells. In these,
exosomal micro RNA 135b (miR-135b) indirectly
increased HIF-1a in endothelial cells through suppression
of Factor Inhibiting HIF-1a, thereby increasing endothelial
tubule formation as a model for angiogenesis [85].
Breast Cancer
One pathway in breast cancer that occurs downstream of
hypoxia and HIF-1a involves transforming growth factor
(TGF)-b signalling. Hypoxia drives HIF-1a signalling in
parallel with TGF-b in the estrogen receptor negative
(ER-) human cell line MDA-MB-231 under in vitro and in
in vivo conditions. Hypoxia induces HIF-1a expression in
human MDA-MB-231 cells in vitro and at sites of bone
metastasis in vivo. Knockdown of HIF-1a reduces forma-
tion of osteolytic bone lesions in mice and decreases
staining for the endothelial cell marker CD31, a marker for
angiogenesis in sites of bone metastasis. HIF-1a knock-
down or TGF-b blockade has also been shown to reduce
bone metastasis and increase survival in mice implanted
orthotopically with human MDA-MB-231 breast cancer
cells [86]. The interaction between HIF and TGF-b may be
mediated by microRNAs, since HIF induces miR-191,
which in turn promotes TGF-b signalling. miR-191 also
promotes proliferation, migration and invasion of human
MCF7 breast cancer cells, while protecting against radia-
tion induced cell death, suggesting a mechanism for
hypoxia-induced resistance to radiotherapy [87].
Notch signalling is also an important signalling pathway
in breast cancer which interacts with hypoxia in a bi-di-
rectional manner. Hypoxia increases the expression of
Notch receptors and ligands in breast cancer cells, possibly
via co-ordinated activity of HIFs and the drosophila mas-
termind homologue, mastermind-like protein 1, a tran-
scriptional co-activator in Notch signalling. This is
associated with increased expression of slug and snail
genes while decreasing E-cadherin in a Notch pathway-
dependent manner to increase cell invasiveness via EMT
[88] reminiscent of that seen in MM. Thus, hypoxia acts
via Notch signalling to trigger EMT via the Snail-1 pro-
moter and to induce cell invasion. Notch increases Snail-1
via two mechanisms; firstly, it has a direct interaction with
the Snail-1 promoter; secondly there is an intriguing syn-
ergistic mechanism whereby Notch up-regulated expres-
sion of the enzyme lysyl oxidase (LOX), which stabilises
the Snail-1 protein once translated [89].
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The Emerging Role of Lysyl Oxidase in Bone
Metastasis
Although lysyl oxidase (LOX) is most well known for
being a collagen cross-linking enzyme, it has more recently
been shown that LOX is an important factor in solid
tumour progression. Tumour-derived LOX expression is
driven by HIF1-a within hypoxic regions in tumours. LOX
drives the motility of the invasive human ER- Hs578T and
human MDA-MB-231 breast cancer cell lines. The LOX
inhibitor b-aminopropionitrile (BAPN) decreases cell
motility in vitro, while focal adhesion kinase (FAK) and
Src activity were positively correlated with LOX. In sup-
port of this, FAK and Src activation were shown to be
decreased in a dose-dependent manner by the small
molecule inhibitor of LOX; BAPN, and by catalase which
degrades the LOX by-product; hydrogen peroxide [90]. We
previously showed that patients with high LOX expressing
ER- tumours exhibit significantly worse distant metastasis-
free survival and poorer overall survival than low LOX
expressing ER- counterparts. siRNA knockdown of LOX
or inhibition with BAPN in human MDA-MB-231 breast
cancer cells reduced hypoxia-driven invasion in nude mice,
demonstrating a clear role for LOX in hypoxia-driven
metastasis [91]. Consistent with these findings, BAPN
injected into mice together with MDA-MB-231 human
breast adenocarcinoma cells reduced number of metastases
and preserved bone volume from osteolytic lesions [92].
Recently, we have added to our understanding of the
seed and soil hypothesis in breast cancer to bone metas-
tasis. We demonstrated that LOX secreted by a distal
mammary tumours triggered osteolytic bone lesion for-
mation. In this landmark study, LOX secreting 4T1 murine
mammary carcinoma cells injected into the mammary fat
pad of syngeneic BALB/c mice triggered bone lesion for-
mation prior to invasion by cells from the primary tumour
and could be abrogated by siRNA knockdown of LOX in
the primary tumour cells. Injection of mice with condi-
tioned media from 4T1 cells in a cell-free tumour-simu-
lation model also drove lesion formation in bone in the
absence of any primary tumour. This demonstrated that the
secretome of the ER- breast cancer cells was driving an
imbalance in bone homeostasis in favour of osteolytic
degradation. A lack of lesion formation in mice injected
with conditioned media from 4T1 cells with shRNA
knockdown for LOX confirmed a role for the enzyme.
Histological analysis of femora from mice carrying 4T1
LOX secreting tumours revealed a reduction in osteoblast
numbers concomitantly with an increase in osteoclast
numbers, an effect that was abrogated by shRNA LOX
knockdown in the primary tumour. Under the established
model of osteoclast generation, both MCSF and RANKL
cytokines are required for monocyte cell fusion and gen-
eration of functional osteoclasts [93]. However, culturing
of enriched human CD14 ? monocytes in the absence of
RANKL but in the presence of LOX led to osteoclast
formation via increased translocation to the nucleus of
NFATc1, the master regulator of osteoclastogenesis. This
effect was abrogated by using a LOX function-blocking
antibody (targeting the active site of the enzyme), and by a
dose-dependent treatment with catalase to remove LOX-
generated hydrogen peroxide. Meanwhile, LOX activity
reduced the proliferation of both primary murine calvarial
osteoblasts and the human osteoblast like SaOS-2 line
pushing these cells toward a more terminally differentiated
phenotype with increased mineralisation. The in vivo
effects of tumour secreted LOX on pre-metastatic bone
lesion formation were preventable if mice were simulta-
neously treated with the potent bisphosphonate Zoledronic
acid to prevent bone lesion formation [94]. This study
opened up the possibility that bisphosphonate treatment
can be used to help prevent metastasis of breast cancer to
bone. At the same time, a large meta-study from the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG)
found that in post-menopausal women with breast cancer,
the adjuvant treatment with bisphosphonates to block
osteoporosis-driven bone remodelling led to a significant
decrease in metastatic bone burden [95]. Together, these
data suggest that targeting the remodelling of the bone
microenvironment offers a viable therapeutic approach to
blocking breast cancer to bone metastasis.
In contrast, studies by Tsukasaki et al. and Reynaud
et al. observed an absence of osteoclast formation in the
presence of LOX and in RANKL knockout models
[96, 97]. However, the apparent contradictory nature of
these findings may be explained by differences in experi-
mental approach. In particular, Tsukasaki et al. used a
truncated form of LOX that lacks the pro-peptide and part
of the mature protein sequence, which together with larger
N-terminal and His6 tags used for purification, could leave
the enzyme without catalytic activity [98]. Studies by
Reynaud et al., whilst supporting the overall findings of
hypoxia-induced LOX expression in metastatic dissemi-
nation to the bone, they did not specify the exact form of
LOX used [97]. It is also worth noting that unlike Cox et al.
where human CD14 ? monocytes were selected isolated
and purified from human peripheral blood [94], Reynaud
et al. also used a heterogeneous mixture of murine bone
marrow cells [97] where the combined response to LOX
remains to be fully understood. Tsukasaki et al. and Rey-
naud et al. did however find that LOX activity strongly
synergises with, and amplifies RANKL action to signifi-
cantly enhance osteoclastogenesis [96, 97], and Reynaud
et al. also found that tumour-secreted LOX generates bone
lesions consistent with findings by Cox et al. [94, 97].
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Regardless, there is a clear need for further research into
the precise molecular mechanisms underlying LOX-driven
osteoclastogenesis.
Summary and Future Directions
This review has covered some of the multitude of mecha-
nisms that underlie unfavourable outcomes in hypoxia-
driven aspects of cancer-associated bone disease. For pri-
mary bone cancers, survival rates have increased decade on
decade as diagnosis methods and treatments have improved
[6]. New hypoxia targeting drugs offer hope of increasing
survival rates further. The best outcomes for patients with
other cancers will be connected to prevention of metastasis
to bone, which will come from new understandings about
the underlying early mechanisms as exemplified by our
own work. For those patients who are diagnosed after this
transition step has occurred, the outlook remains one of
managed decline, as the cancer is transiently held back
with surgery, radiotherapy, and combination therapies.
This significant challenge currently lies unresolved, yet
perhaps one day secondary metastatic bone cancers will not
just be manageable or treatable but curable too.
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